Comprehensive analysis of ATF3 as a diagnostic and prognostic biomarker from pan-cancer to clear cell renal cell carcinoma
A cancer marker linked to worse outcomes and weak immune response could help predict which patients benefit most from immunotherapy.
Using public pan-cancer databases, ATF3 was found to be broadly downregulated with tumor-suppressive and prognostic implications across cancer types; in ccRCC specifically, low ATF3 correlated with worse outcomes and immune infiltration patterns suggesting a potential immunotherapy sensitizer. Findings are database-derived and require prospective clinical validation.
What the study was
- Study design
- Bioinformatics/computational pan-cancer analysis with cell-line validation
- Population
- Pan-cancer (public database); clear cell renal cell carcinoma cell lines
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Discover Oncology
Why it surfaced
Database-mining pan-cancer ATF3 study; moderately relevant for precision oncology surveillance in ccRCC context. Design is bioinformatics-only with cell line validation, limiting score. Deferred from 2026-04-30 run.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.